Exome-Based Rare-Variant Analyses in CKD.

Abstract

Studies have identified many common genetic associations that influence renal function and all-cause CKD, but these explain only a small fraction of variance in these traits. The contribution of rare variants has not been systematically examined. We performed exome sequencing of 3150 individuals, who collectively encompassed diverse CKD subtypes, and 9563 controls. To detect causal genes and evaluate the contribution of rare variants we used collapsing analysis, in which we compared the proportion of cases and controls carrying rare variants per gene. The analyses captured five established monogenic causes of CKD: variants in <i>PKD1</i>, <i>PKD2</i>, and <i>COL4A5</i> achieved study-wide significance, and we observed suggestive case enrichment for <i>COL4A4</i> and <i>COL4A3</i>. Beyond known disease-associated genes, collapsing analyses incorporating regional variant intolerance identified suggestive dominant signals in <i>CPT2</i> and several other candidate genes. Biallelic mutations in <i>CPT2</i> cause carnitine palmitoyltransferase II deficiency, sometimes associated with rhabdomyolysis and acute renal injury. Genetic modifier analysis among cases with <i>APOL1</i> risk genotypes identified a suggestive signal in <i>AHDC1</i>, implicated in Xia-Gibbs syndrome, which involves intellectual disability and other features. On the basis of the observed distribution of rare variants, we estimate that a two- to three-fold larger cohort would provide 80% power to implicate new genes for all-cause CKD. This study demonstrates that rare-variant collapsing analyses can validate known genes and identify candidate genes and modifiers for kidney disease. In so doing, these findings provide a motivation for larger-scale investigation of rare-variant risk contributions across major clinical CKD categories.